

ASSIGNMENT

WHEREAS, we, Julie D. Saba and Henrik Fyrst (hereinafter referred to as ASSIGNORS), having mailing addresses of 6630 Banning Drive, Oakland, California 94611, and 1411 Grant Street, #3, Alameda, California 94501, respectively, are the joint inventors of an invention entitled "SPHINGOSINE-1-PHOSPHATE LYASE POLYPEPTIDES, POLYNUCLEOTIDES AND MODULATING AGENTS AND METHODS OF USE THEREFOR," as described and claimed in the specification for which an application for United States letters patent was filed on January 17, 2002 and assigned Application No. 10/053,510.

WHEREAS, Children's Hospital & Research Institute at Oakland (hereinafter referred to as ASSIGNEE), a non-profit organization of the State of California having a place of business at 5700 Martin Luther King Jr. Way, Oakland, California 94609-1673, is desirous of acquiring the entire right, title and interest in and to the invention and in and to any letters patent that may be granted therefor in the United States and in any and all foreign countries;


NOW, THEREFORE, in exchange for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNORS hereby sell, assign and transfer unto said ASSIGNEE the entire right, title and interest in and to said invention, said application and any and all letters patent which may be granted for said invention in the United States of America and its territorial possessions and in any and all foreign countries, and in any and all divisions, reissues and continuations thereof, including the right to file foreign applications directly in the name of ASSIGNEE and to claim priority rights deriving from said United States application to which said foreign applications are entitled by virtue of international convention, treaty or otherwise, said invention, application and all letters patent on said invention to be held and enjoyed by ASSIGNEE and its successors and assigns as fully and entirely as the same would have been held and enjoyed by ASSIGNORS had this assignment, transfer and sale not been made. ASSIGNORS hereby authorize and request the Commissioner of Patents and Trademarks to issue all letters patent on said invention to ASSIGNEE. ASSIGNORS agree to execute all instruments and documents required for the making and prosecution of applications for United

States and foreign letters patent on said invention, for litigation regarding letters patent, or for the purpose of protecting title to said invention or letters patent therefor.

5-28-02	Julie Sala				
Date	Julie D. Saba				
State of <u>CALIFORNIA</u>)	SS.				
County of ALAMEDA)					

I certify that I know or have satisfactory evidence that Julie D. Saba is the person who appeared before me, and said person acknowledged that she signed this instrument and acknowledged it to be her free and voluntary act for the uses and purposes mentioned in the instrument.

Dated	5-28-02
Signature of Notary Public	Linda La Invoniar
Printed Name	LINDA L Tywoniak
My appointme	,



Application No. 10/053,510

	5-28.02	1 h-1				
Date		Henrik Fyrst				
State of	CALIFORNIA)					
County of	ALAMEDA)	SS.				

I certify that I know or have satisfactory evidence that Henrik Fyrst is the person who appeared before me, and said person acknowledged that he signed this instrument and acknowledged it to be his free and voluntary act for the uses and purposes mentioned in the instrument.

Dated	5.2802		
Signature of	J		
Notary Public	Linda	L'Eywonish	
•		· // .	
Printed Name	LINDA	L Tywoniak	
		7	
My appointmen	nt expires	5-11-05	

(JAU:cew) #252009 200116.402C2





PTO/SB/01A (10-00).

Asproved for use through 10/31/2002. OMB 0651-0032. U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE. Under the Page Prork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

RADEN DECL ARATION (27.000 4.0

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	SPHINGOSINE-1-PHOSPHATE LYASE POLYPEPTIDES, POLYNUCLEOTIDES AND MODULATING AGENTS AND METHODS OF USE THEREFOR							
As the below named inventor(s), I/we declare that:								
This declaration is directed to:								
☐ The attached application, or								
x Application	Application No. 10/053,510, filed on January 17, 2002,							
as ame	nded on (if applicable);							
I/we believe that I/we a which a patent is sough	m/are the original and first inventor(s) on t;	of the subject	matter which is claimed and for					
	I understand the contents of the abovedment specifically referred to above;	identified app	lication, including the claims, as					
known to me/us to be which became available	duty to disclose to the United States material to patentability as defined in a between the filing date of the prior appuation-in-part application, if applicable; a	37 CFR 1.56 dication and the	, including material information					
and belief are believed willful false statements	erein of my/our own knowledge are true to be true, and further that these state and the like are punishable by fine or it validity of the application or any patent	tements were mprisonment,	made with the knowledge that or both, under 18 U.S.C. 1001,					
FULL NAME OF INVEN	ITOR(S)							
Inventor one: Julie	D. Saba	Citizen of:	United States					
Signature:	Juie Jasa	Date:	5.28-02					
Inventor two: Henri	ik Fyrst	Citizen of:	Denmark					
Signature:	2/ por	Date:	5-28-02					
Inventor three:		Citizen of:						
Signature:		Date:						
Inventor four:		Citizen of:						
Signature:	e: Date:							
Additional inventors are being named on additional form(s) attached hereto.								

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.] (JAU:cew) #252010



No.: EL755731162US

PTO/SB/81 (10-00)
Approved for use through 10/31/2002. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it displays a valid OMB control survey. Under the Paperwork Reduction Act of 1995, no persons

LECTION AND POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

are required to respond to a confection of minormation unless it displays a valid OND control number					
Application Number	10/053,510				
Filing Date	January 17, 2002				
First Named Inventor	Julie D. Saba				
Group Art Unit					
Examiner Name					
Attorney Docket Number	200116.402C2				

I hereby app Practitions OR Practitione	ers at See		Group PLI	LC		_		PATE	0050 NT TRADEMAI	-	
				ute the ap	oplication	n identifie	Registrati			ss in the Pa	atent and
Trademark Office connected therewith. Please change the correspondence address for the above-identified application to: The above-mentioned Customer Number. OR											
∏ Firm <i>or</i> Individual	Name										
Address								<u></u>			
Address											
City						State		ZI	P		
Country											
Telephone						Fax			_		
I am the: Applicant/Inventor. Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96). As assignee of record of the entire interest hereby elect, under 37 C.F.R. § 3.71, to prosecute the application to the exclusion of the inventor											
SIGNATURE of Applicant or Assignee of Record											
Name [*]	Antonie I	Н. Раар		_		:					
Signature	A	~	$\overline{\ }$								
Date	6/21	102	-() -	/							
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.											

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231. #290334 200116.402C2

OIPE COST

PTO/SB/96 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, `no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Julie D. Saba et al. Filed/Issue Date: <u>January 17, 2002</u> Application No./Patent No.: 10/053,510 Entitled: SPHINGOSINE-1-PHOSPHATE LYASE POLYPEPTIDES, POLYNUCLEOTIDES AND MODULATING AGENTS AND METHODS OF USE THEREFOR Children's Hospital & Research Institute at Oakland, Non-profit organization (Type of Assignee, e.g., corporation, partnership, (Name of Assignee) university, government agency, etc.) states that it is: 1. x the assignee of the entire right, title, and interest; or 2. an assignee of an undivided part interest in the patent application/patent identified above by virtue of either: A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached. **OR** B. | A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below: 1. From:____ To: The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached

Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title are attached.

Reel _____, Frame _____, or for which a copy thereof is attached

Reel _____, Frame _____, or for which a copy thereof is attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.8]

The document was recorded in the United States Patent and Trademark Office at

The document was recorded in the United States Patent and Trademark Office at

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Antonie H. Paap

Date

Typed or printed name

Signature

President and CEO

Title

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

2. From:

From: